(Q43750756)

26 November 2017

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study (English)

1 reference

26 November 2017

1 reference

1 reference

1 reference

P Papakostas

1

1 reference

26 November 2017

C Kouroussis

2

1 reference

26 November 2017

N Androulakis

3

1 reference

26 November 2017

G Samelis

4

1 reference

26 November 2017

G Aravantinos

5

1 reference

26 November 2017

K Kalbakis

6

1 reference

26 November 2017

E Sarra

7

1 reference

26 November 2017

J Souglakos

8

1 reference

26 November 2017

S Kakolyris

9

1 reference

26 November 2017

V Georgoulias

10

1 reference

26 November 2017

language of work or name

1 reference

1 October 2001

1 reference

European Journal of Cancer

26 November 2017

1 reference

26 November 2017

37

1 reference

26 November 2017

15

1 reference

26 November 2017

1833-1838

1 reference

Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900214-3

7 January 2021

10.1016/S0959-8049(01)00214-3

Identifiers

DOI

1 reference

26 November 2017

1 reference